Syneron Bio

Isomorphic Labs is a drug discovery company spun out of DeepMind and founded in 2022 in London, applying AI to drug discovery and design including protein structure prediction via AlphaFold.

Inductive Bio, founded in 2022 in San Francisco, uses AI to simulate protein-molecule interactions for drug discovery.

Accipiter Bio, founded in 2023 in Seattle, USA, uses AI to design multi-target degrader drugs (novel protein-degrading therapeutics).

Pepper Bio, founded in 2018 in Massachusetts, USA, analyzes multi-layered biological data—including DNA, RNA, proteomic, and phosphoproteomic data—to discover novel drug candidates.

Anew Labs is an AI-driven drug discovery company spun out of ByteDance. Its team was formed inside ByteDance in 2021 by Liu Kai and was spun off as an independent company in June 2026, headquartered in Yangpu, Shanghai, with offices in the US and Singapore. It builds AI drug-discovery platforms (AnewFold, AnewSampling, AnewOmni, AnewDesign, AnewMind) spanning protein structure prediction, all-atom molecular generation, antibody design and scientific reasoning, with a pipeline of preclinical candidates including a small-molecule inhibitor targeting IL-17 family dimers.

BigHat Biosciences, founded in 2019 by Mark DePristo and Peyton Greenside and based in San Mateo, California, is an AI-native biotech whose Milliner platform couples frontier AI with autonomous high-throughput experimentation to design antibody and protein therapeutics; its lead asset BHB810, a CDH17-targeted ADC, is in Phase I, and it partners with Amgen, Merck, AbbVie, J&J and Lilly.